Triple cholesterol punch: could three drugs beat two after a heart attack?

NCT ID NCT07508254

Not yet recruiting Disease control Sponsor: Punjab Institute of Cardology Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a three-drug combination (atorvastatin, ezetimibe, and bempedoic acid) against the usual two-drug therapy for lowering LDL cholesterol in people who have had a heart attack or unstable angina. About 120 adults will take either the triple or dual therapy for 3 months. Researchers will measure how much their cholesterol drops and watch for any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atorvastatin, ezetimibe, and bempedoic acid (three cholesterol-lowering drugs)
What this could lead to: If it works, this could point toward a more effective way to lower cholesterol after a heart attack, potentially reducing the risk of future heart problems.
What could go wrong: This is a small, early-phase trial with only 120 participants, so results may not apply to everyone. The triple therapy may cause more side effects or not be significantly better than the standard dual therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROMES (ACS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome Hypercholesterolemia hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CORONARY SYNDROMES (ACS) HYPERCHOLESTEROLEMIA

Contacts and locations

Locations

Punjab Institute of Cardiology

Lahore, Punjab Province, 56000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.